RenovoRx Creates RenovoCath Medical Advisory Board For Its Clinical, Strategic Initiatives

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the formation of a dedicated RenovoCath Medical Advisory Board ("MAB") to support its clinical and strategic initiatives.

The MAB brings together leading US interventional radiology experts to provide strategic clinical insights that further advance the TAMP (Trans-Arterial Micro-Perfusion) therapy platform in clinical indications of high unmet medical need. The MAB compliments the Company's esteemed and long-standing Scientific Advisory Board that provides specialized guidance on RenovoRx's scientific research and clinical program strategy.